RFP: Combination Therapy with Relugolix in the Treatment of Advanced Prostate Cancer

Sponsor Deadline: 

May 22, 2023


National Comprehensive Cancer Network, Pfizer, and Myovant

UI Contact: 

The overall aim is to develop innovative studies to advance scientific knowledge regarding combination therapies with relugolix in the treatment of patients with advanced prostate cancer, including high-risk or locally advanced primary, recurrent, or metastatic, in any state (androgen-sensitive or castrationresistant).

It is hoped that proposals submitted in response to this RFP will be useful to guide further development of relugolix. Studies with correlative endpoints are encouraged.

See the Request for Proposals (pdf)